Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer

By E. Tran, S. Turcotte, A. Gros, P. Robbins, Yong-Chen Lu, M. Dudley, J. Wunderlich, R. Somerville, Katherine A. Hogan, C. Hinrichs and 3 more. Science, 2014

1,637 citations recorded by the source corpus.

Subfields: Immunology, Oncology

View Paper: https://www.semanticscholar.org/paper/a4c7382a05904647c796274a31b18e434a1d540f

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

1. Padmanee Sharma
2. P. Greenberg
3. James P. Allison
4. A. Schietinger
5. M. Philip
6. S. Shalapour
7. M. Karin

In Oncology

1. Padmanee Sharma
2. P. Greenberg
3. James P. Allison
4. A. Schietinger

Citations in the corpus

• Systemic Immunity is Required for Effective Cancer Immunotherapy (2017, neutral): “Many studies have focused on CD8 T cells (Chen and Mellman, 2013; Im et al., 2016), with less emphasis on harnessing CD4 T cells (Tran et al., 2014; Xie et al., 2010).”
• Neoantigens: promising targets for cancer therapy (2023, background): “Retrospective analysis of the infusion product has shown that the CD4 T-helper 1 cells were reactive to an ERBB2IP mutation, suggesting a potential function of neoantigenspecific CD4 T cells in the control of a metastatic epithelial cancer.(386) TILs from individuals with metastatic gastrointestinal”
• A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T cell receptor: Long term follow up and correlates with response (2014, neutral): “4 19/M lu S, R, C (1) 16 5 46/40 31/25 5 30/M pl, hi S, C (2) 59 5 92/8 68/5 6 40/M pl, hi S, R, C (3) 52 5 81/18 63/12 7 64/F bo, lu S, R, C (5) 39 5 83/17 72/13 8 37/M lu S, C (2) 22 6 87/13 66/4 9 21/F lu S, R, C (1) 77 1 89/11 56/6”